Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis.
Daamen LA, Groot VP, Besselink MG, Bosscha K, Busch OR, Cirkel GA, van Dam RM, Festen S, Groot Koerkamp B, Haj Mohammad N, van der Harst E, de Hingh IHJT, Intven MPW, Kazemier G, Los M, Meijer GJ, de Meijer VE, Nieuwenhuijs VB, Pranger BK, Raicu MG, Schreinemakers JMJ, Stommel MWJ, Verdonk RC, Verkooijen HM, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group. Daamen LA, et al. Ann Surg. 2022 Apr 1;275(4):769-775. doi: 10.1097/SLA.0000000000004093. Ann Surg. 2022. PMID: 32773631
OBJECTIVE: To evaluate whether detection of recurrent pancreatic ductal adenocarcinoma (PDAC) in an early, asymptomatic stage increases the number of patients receiving additional treatment, subsequently improving survival. ...Overall survival (OS) was …
OBJECTIVE: To evaluate whether detection of recurrent pancreatic ductal adenocarcinoma (PDAC) in an early, asymp …
Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma.
Welsch T, Keleg S, Bergmann F, Degrate L, Bauer S, Schmidt J. Welsch T, et al. Clin Exp Metastasis. 2009;26(7):701-11. doi: 10.1007/s10585-009-9269-4. Epub 2009 Jun 2. Clin Exp Metastasis. 2009. PMID: 19488831
The prominent CD133 pattern was an apical membrane staining of inflammatorily altered, non-neoplastic ductal structures equally observed in primary and recurrent PDAC. The membrane CD133 positivity was consistently absent in neoplastic PDAC cells. ...
The prominent CD133 pattern was an apical membrane staining of inflammatorily altered, non-neoplastic ductal structures equally observed …
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Fu Q, Chen Y, Huang D, Guo C, Zhang X, Xiao W, Xue X, Zhang Q, Li X, Gao S, Que R, Shen Y, Wu J, Zhang M, Bai X, Liang T. Fu Q, et al. Ann Surg Oncol. 2023 Aug;30(8):5071-5080. doi: 10.1245/s10434-023-13383-w. Epub 2023 Apr 13. Ann Surg Oncol. 2023. PMID: 37052821 Clinical Trial.
We evaluated the efficacy and safety of sintilimab with mFFX for metastatic/recurrent pancreatic ductal adenocarcinoma in China. PATIENTS AND METHODS: This was a single-center, randomized, controlled, open-label phase II study. ...CONCLUSIONS: The stud …
We evaluated the efficacy and safety of sintilimab with mFFX for metastatic/recurrent pancreatic ductal adenocarcino …
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S. Gbolahan OB, et al. BMC Cancer. 2019 May 17;19(1):468. doi: 10.1186/s12885-019-5630-4. BMC Cancer. 2019. PMID: 31101022 Free PMC article.
Patients derive significant benefit from these standard combination therapies with median OS that is comparable to what is observed with treatment for de novo mPDAC....
Patients derive significant benefit from these standard combination therapies with median OS that is comparable to what is observed w …
The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Kitamura H, Nakazawa J, Nagashima F, Andou M, Furuse J. Kitamura H, et al. Intern Med. 2023 Jun 1;62(11):1573-1580. doi: 10.2169/internalmedicine.9689-22. Epub 2022 Oct 12. Intern Med. 2023. PMID: 36223928 Free PMC article.
Objective To evaluate the effect of a pretreatment geriatric assessment on the clinical outcomes in older patients with unresectable or recurrent pancreatic ductal adenocarcinoma (PDAC) scheduled to receive gemcitabine (GEM)/GEM+nab-paclitaxel (GnP). . …
Objective To evaluate the effect of a pretreatment geriatric assessment on the clinical outcomes in older patients with unresectable or r …